Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IGF2R | P11717 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550356 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL104855 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL7549080 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL284741 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL1521155 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL9208454 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL24021536 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL1521609 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL7549072 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL1521156 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | disclosed |